

Supplementary Table S1. Baseline demographic, clinical and pre-TCZ therapeutic characteristics stratified by clinical response.

Characteristic	remission group (n=22)	non-remission group (n=18)	p-value
Female, n (%)	17 (77.3)	15 (83.3)	0.634
Age, median (IQR), years	38.0 (22.5-51.5)	35.0 (22.0-52.5)	0.775
Disease duration, median (IQR), months	2.0 (1.0-30.0)	8.0 (1.5-12.5)	0.620
Follow-up duration, median (IQR), months	13.0 (9.8-18.3)	15.0 (13.5-23.5)	0.117
Pouchot score, median (IQR)	4.0 (1.5-6.0)	6.0 (4.0-7.5)	*0.017
PGA, median (IQR), 0-10	5.0 (3.5-6.0)	6.0 (5.0-7.5)	*0.007
MDGA, median (IQR), 0-10	5.0 (3.5-6.0)	6.0 (5.0-7.5)	*0.006
WBC, median (IQR), $\times 10^9/L$	10.9 (7.6-16.9)	9.3 (8.3-14.2)	0.550
NE, median (IQR), $\times 10^9/L$	10.1 (6.1-14.4)	8.0 (7.1-11.8)	0.334
LYM, median (IQR), $\times 10^9/L$	1.2 (1.0-1.8)	0.9 (0.6-1.4)	0.136
Hb, median (IQR), g/L	112.0 (103.0-123.5)	107.0 (97.5-116.5)	0.165
PLT, mean $\pm$ SD, $\times 10^9/L$	308.9 $\pm$ 131.1	232.5 $\pm$ 114.9	0.655
ALT, median (IQR), IU/L	17.0 (10.5-25.5)	56.0 (27.5-141.5)	*0.014
AST, median (IQR), IU/L	22.0 (18.0-35.0)	59.0 (36.0-115.5)	*0.002
LDH, median (IQR), IU/L	289.0 (246.5-405.5)	520.0 (377.5-781.0)	*0.009
CRP, median (IQR), mg/L	38.4 (15.4-83.3)	45.1 (14.5-96.8)	0.532
ESR, median (IQR), mm/H	39.0 (28.0-85.5)	36.0 (14.5-75.5)	0.939
SF, median (IQR), $\mu g/L$	1642.0 (263.5-4199.5)	3319.0 (1357.5-10134.0)	*0.031
Treatment			
Prednisone dose, median (IQR), mg/d	50.0 (27.5-72.5)	50.0 (30.0-75.0)	0.913
Prior csDMARDs/JAKi, n (%)			
Methotrexate	11 (50.0)	6 (33.3)	0.433
Hydroxychloroquine	4 (18.2)	2 (11.1)	0.533
Cyclosporin A	2 (9.1)	2 (11.1)	0.832
Leflunomide	1 (4.5)	2 (11.1)	0.433
Mycophenolate mofetil	1 (4.5)	1 (5.6)	0.884
Tofacitinib	4 (18.2)	0 (0.0)	0.057
Baricitinib	2 (9.1)	1 (5.6)	0.673
Ruxolitinib	1 (4.5)	1 (5.6)	0.884

Data are presented as n (%), mean $\pm$ SD, or median (Q1, Q3). P-values are for comparisons between remission group and non-remission group. * $p < 0.05$.

Patients who discontinued due to adverse events were classified as non-remission group for the primary outcome analysis.

IQR: interquartile range; SD: standard deviation; PGA: patient's global assessments; MDGA: medical doctor's global assessments; WBC: white blood cell count; NE: neutrophils; LYM: lymphocyte; Hb: haemoglobin; PLT: platelet; ALT: alanine aminotransferase; AST: aspartate aminotransferase; LDH: lactate dehydrogenase; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; SF: serum ferritin; DMARDs: disease-modifying antirheumatic drugs; JAKi: Janus kinase inhibitors.

Supplementary Table S2. Baseline demographic, clinical and pre-TCZ therapeutic characteristics stratified by clinical presentation.

Characteristic	Systemic (n=29)	Articular (n=11)	p-value
Female, n (%)	23 (79.3)	9 (81.8)	0.859
Age, median (IQR), years	34.0 (24.0-54.0)	39.0 (23.0-70.8)	0.554
Disease duration, median (IQR), months	1.0 (5.0-64.0)	8.0 (1.0-13.0)	0.724
Follow-up duration, median (IQR), months	16.0 (9.0-21.0)	14.0 (8.0-28.0)	0.617
Pouchot score, median (IQR)	5.0 (2.5-6.3)	5.5 (2.5-8.0)	0.604
PGA, median (IQR), 0-10	6.0 (4.3-7.5)	6.0 (5.0-6.0)	0.804
MDGA, median (IQR), 0-10	6.0 (4.3-7.5)	6.0 (5.0-6.0)	0.686
WBC, median (IQR), $\times 10^9/L$	9.5 (5.9-13.1)	11.9 (10.1-17.8)	0.244
NE, median (IQR), $\times 10^9/L$	8.0 (4.5-13.1)	10.1 (7.5-15.4)	0.565
LYM, median (IQR), $\times 10^9/L$	1.0 (0.6-1.6)	1.5 (0.9-2.2)	0.168
Hb, median (IQR), g/L	118.5 (103.5-141.5)	105.0 (98.5-115.8)	0.355
PLT, mean $\pm$ SD, $\times 10^9/L$	237.0 $\pm$ 132.6	298.0 $\pm$ 139.2	0.437
ALT, median (IQR), IU/L	35.0 (10.0-42.3)	15.0 (11.3-43.8)	0.208
AST, median (IQR), IU/L	38.5 (16.8-54.5)	22.0 (13.3-56.3)	0.174
LDH, median (IQR), IU/L	401.5 (159.3-407.3)	289.0 (247.0-475.3)	0.643
CRP, median (IQR), mg/L	45.1 (2.3-78.4)	29.8 (20.0-67.0)	0.317
ESR, median (IQR), mm/H	36.0 (5.8-52.0)	32.5 (15.3-87.3)	0.973
SF, median (IQR), $\mu g/L$	1642.0 (220.1-6575.8)	1453.0 (141.6-4239.8)	0.311
Treatment			
Prednisone dose, median (IQR), mg/d	50.0 (20.0-75.0)	40.0 (15.0-60.0)	0.508
Prior csDMARDs/JAKi, n (%)			
Methotrexate	12 (41.4)	5 (45.5)	0.816
Hydroxychloroquine	5 (17.2)	1 (9.1)	0.519
Cyclosporin A	3 (10.3)	1 (9.1)	0.906
Leflunomide	2 (6.9)	1 (9.1)	0.814
Mycophenolate mofetil	1 (3.4)	1 (9.1)	0.465
Tofacitinib	2 (6.9)	2 (18.2)	0.288
Baricitinib	1 (3.4)	2 (18.2)	0.114
Ruxolitinib	0 (0.0)	2 (18.2)	0.018

Data are presented as n (%), mean $\pm$ SD, or median (Q1, Q3). *p*-values are for comparisons between systemic and articular patterns. * *p*<0.05.

IQR: interquartile range; SD: standard deviation; PGA: patient's global assessments; MDGA: medical doctor's global assessments; WBC: white blood cell count; NE: neutrophils; LYM: lymphocyte; Hb: haemoglobin; PLT: platelet; ALT: alanine aminotransferase; AST: aspartate aminotransferase; LDH: lactate dehydrogenase; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; SF: serum ferritin; DMARDs: disease-modifying antirheumatic drugs; JAKi: Janus kinase inhibitors.

Supplementary Table S3. Sensitivity analyses for the association between baseline serum ferritin and disease remission.

Analysis	Serum ferritin cutoff ($\mu g/L$)	OR	95% CI	p-value
Primary analysis	$\geq 2500 \mu g/L$	0.144	0.036-0.582	*0.006
Sensitivity analyses	$\geq 1000 \mu g/L$	0.410	0.100-1.689	0.217
	$\geq 1500 \mu g/L$	0.450	0.117-1.724	0.244
	$\geq 2000 \mu g/L$	0.220	0.057-0.846	*0.028
	$\geq 3000 \mu g/L$	0.278	0.070-1.109	0.070

OR: odds ratio; CI: confidence interval. * *p*<0.05.